Verve Therapeutics Inc., a clinical-stage company specializing in genetic medicines for cardiovascular disease, has announced new equity awards under its 2024 Inducement Stock Incentive Plan. On May 30, 2025, the company granted stock options for a total of 65,000 shares and 22,000 restricted stock units (RSUs) to four new employees. The stock options have an exercise price of $4.45 per share, reflecting the closing price on the grant date, and will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. The RSUs will vest in equal annual installments over three years, beginning on July 1, 2025.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。